Effects of exogenous Glucagon-Like Peptide-1 (GLP-1) administration on gastric emptying during hyperglycaemic clamp experiments in healthy volunteers.

Dr Mark Plummer0 个研究点目标入组 15 人开始时间: 2013年12月17日最近更新: 2020年1月13日

适应症

试验速览

暂无简介。

•15 healthy volunteers, with no history of diabetes, minimal alcohol and nicotine consumption and BMI <32, aged 50-80 years

•Exclusion criteria will comprise
•-Inability to give informed consent
•-Known diabetes mellitus or a glycated haemoglobin (HbA1c) >/=6.5%
•-Abnormal ferritin levels, haemoglobin levels or liver function on screening
•-Previous gastrointestinal surgery
•-Taking medications known to affect gastrointestinal motility or blood sugar.
•This includes: insulin, oral hypoglycaemic agents (metformin, sulphonylureas, acarbose), antibiotics, steroids, proton pump inhibitors, amtiemetics, prokinetic agents and H2 receptor antagonists.
•-Body Mass Index >32kg/m2
•-Smoking >10 cigarettes/day
•-Alcohol consumption >20g/day
•-Previous exposure to radiation for research purposes in the preceding 12 months
•-Volunteers who have donated blood in the preceding 3 months
•-Female volunteers of child bearing age who are pregnant or lactating, or who have inadequate contraception
•-Suffer from any chronic medical condition such as (but not limited to) heart failure, ischaemic heart disease, chronic lung disease, autonomic dysfunction resulting from any cause, active or previously treatment malignancy, chronic infections (e.g. viral hepatitis and HIV)
•-Taking any prescription or over the counter medications other than simple analgesics (e.g. paracetamol)
•-Suffered from any acute medical illness (e.g. upper respiratory tract infection, pneumonia...etc) during the 4 week period before recruitment

发起方

Dr Mark Plummer